Catestatin peptide reduces neurodegeneration markers in mouse models

Researchers at the University of California San Diego have reported that catestatin, a naturally occurring peptide, reduced disease-related protein changes and inflammation in mouse models of neurodegeneration. Highlighted by the university on September 22, the findings identify a possible route for drug development aimed at preserving brain function, while leaving human effectiveness and safety unresolved.

The study appears in Molecular Therapy. An earlier version was posted as a preprint in January 2026, so this week’s development is its journal publication and accompanying university announcement. It does not represent the first public disclosure of the underlying research or a new clinical trial.

What the experiments found

The investigation combined measurements in human brain tissue with experiments in neuronal cultures, brain-slice cultures and genetically engineered mice. These components answer different questions: tissue measurements can identify disease-associated differences, while experimental treatment can test whether changing a pathway affects outcomes in a model.

The researchers reported lower catestatin levels in brain regions from people with Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy. Those observations do not establish that a catestatin deficiency caused the disorders or that replacing the peptide would help patients.

In laboratory cultures, adding catestatin reduced tau phosphorylation and aggregation—chemical modification and accumulation of a protein implicated in several neurodegenerative conditions. In PS19 mice, a model of tau-related disease, treatment reduced pathological tau and glial activation and improved cognitive performance. In a separate model, 5xFAD mice, the researchers reported reduced amyloid burden and neuroinflammation.

The distinction between the models matters. Results involving tau and amyloid came from different experimental settings; they should not be read as proof that one intervention comprehensively treats human Alzheimer’s disease.

A possible connection to stress signaling

Catestatin comes from chromogranin A, a protein involved in cellular signaling and hormone and neurotransmitter storage and release. The researchers’ mechanistic findings point toward adrenergic signaling, the system through which messengers such as epinephrine exert their effects.

Catestatin lowered epinephrine levels in both mouse models and reduced excessive activity of protein kinase A in the tau model and brain-slice experiments. The authors interpret these findings as a connection between peptide imbalance, stress signaling and neurodegenerative pathology.

That interpretation provides a testable development hypothesis. It does not establish which biological change is most important for a lasting functional benefit, or whether the same relationships would hold in people with established disease.

What remains before clinical translation

The work’s relevance to healthspan lies in its focus on cognitive and neurological function. It did not demonstrate longer human survival, prevention of dementia or preservation of independence in patients. Mouse behavioral improvements and changes in tissue markers cannot answer those clinical questions.

The university explicitly describes the findings as preclinical and says additional work is needed to establish safety and effectiveness. A peptide’s natural presence in the body also cannot establish the safety of administering it as a medicine. Future development would need to determine whether adequate exposure can be achieved safely and whether benefits persist beyond the experimental conditions studied here.

Commercial interests are disclosed: senior author Sushil K. Mahata founded CgA Therapeuticals and co-founded Siraj Therapeutics, and Mahata and lead author Suborno Jati are named as co-inventors on related intellectual property. Those interests make independent confirmation particularly useful when assessing the development case.

For now, the practical contribution is a set of preclinical findings connecting a specific peptide with several measurable features of neurodegeneration. The evidence supports further investigation; it does not establish catestatin as a treatment for dementia.